2006
This study showed that a single dose of Semax increased BDNF (brain-derived neurotrophic factor, a protein that helps brain cells grow and connect) protein levels by 40% and boosted the activation of its receptor (trkB) in the hippocampus, the brain's memory center. Treated animals performed significantly better on learning tests. This helped explain how Semax improves memory inside brain cells.
Dolotov OV, Karpenko EA, Inozemtseva LS, et al.
2006
Researchers discovered that Semax has specific binding sites in the brain and rapidly increases BDNF (brain-derived neurotrophic factor, a protein that helps brain cells grow) levels after intranasal administration (a spray into the nose). The binding was precise (with a dissociation constant of 2.4 nM; a lower number means tighter binding), confirming Semax isn't just a random peptide. It has a specific target in brain tissue.
Dolotov OV, Karpenko EA, Seredenina TS, et al.
2010
This study mapped how Semax affects two key brain growth factors (NGF and BDNF) across different brain regions. It found that Semax produces a coordinated wave of neurotrophin (growth protein) activation, with effects varying by brain region and timing, revealing Semax's sophisticated, targeted action.
Shadrina M, Kolomin T, Agapova T, et al.
2015
Beyond its BDNF effects, this study revealed that Semax strongly binds copper ions, a metal linked to neurotoxicity (harm to nerve cells) in conditions like Alzheimer's. Semax protected brain cells from copper-induced damage, adding an antioxidant effect (protection against damage from unstable molecules) to its brain-protecting profile.
Tabbi G, Magri A, Giuffrida A, et al.
2025
In mice modeling Alzheimer's disease, both Semax and its derivatives (close chemical relatives) improved thinking and memory on multiple tests (open field, object recognition, maze navigation) and reduced amyloid plaque buildup (clumps of abnormal protein) in the brain. This recent research highlights Semax's potential for neurodegenerative conditions (diseases where brain cells are gradually lost).
Radchenko AI, Kuzubova EV, Apostol AA
2026
Official Russian label for Semax 0.1% nasal drops (RU LP-No.(009449)-(RG-RU), prescription-only, on the Russian Vital and Essential Drugs list). It is a lab-made copy of ACTH(4-10) (a piece of a stress hormone) with no hormonal activity at all. It affects memory formation and learning, improves attention while learning and analyzing information, and strengthens memory consolidation (locking in new memories). It is absorbed through the lining of the nose, crosses the blood-brain barrier (the filter that protects the brain), and does not reach the digestive tract. Uses include problems with thinking caused by cerebrovascular disease (disease of the blood vessels in the brain), the recovery period after stroke, conditions after traumatic brain injury and brain surgery, optic nerve atrophy (wasting of the nerve that connects the eye to the brain) and neuritis (inflammation of that nerve), and (from age 7) minimal brain dysfunction including ADHD. Daily doses: 400-900 mcg to prevent trouble adapting and mental fatigue (given in the first half of the day), 600-900 mcg for optic nerve disease, and up to 800-8000 mcg for thinking problems from cerebrovascular disease. The only listed side effect is mild irritation of the lining of the nose with long use. Must not be used in acute psychiatric states, anxiety disorders, a history of seizures, age under 7, hypersensitivity (allergy to it), pregnancy and breastfeeding.
PEPTOGEN (Innovative Research and Production Center); Vidal Russia
2026
Narrative review (an expert overview, in Front Aging). For Semax: the main mechanism is raising BDNF (a protein that helps brain cells grow and connect): 1.4 times more BDNF protein in the hippocampus, 3 times more BDNF mRNA (the gene copy used to build the protein), and stronger activation of its trkB receptor. This helps nerve cells survive, helps the brain rewire its connections (synaptic plasticity), and helps new neurons grow (neurogenesis). It also adjusts dopamine and serotonin systems (brain chemicals), and antioxidant pathways (protection against damage from unstable molecules) are described. Russian stroke trials showed improved neurological recovery. The review states Semax has decades of use in Russia with apparently good safety records, but lacks independent Western validation and systematic safety monitoring, and is not approved by the FDA or equivalent agencies.
Mavrych V, Shypilova I, Bolgova O
2025
In vitro (in lab dishes): Semax, which binds copper(II) very tightly, pulled copper(II) out of copper(II)-amyloid-beta complexes (copper stuck to amyloid-beta, a sticky protein linked to Alzheimer's). It changed their redox cycling (the chemical back-and-forth that makes damaging molecules) and decreased the related production of reactive oxygen species (damaging unstable oxygen molecules). It protected SH-SY5Y neuronal cells (a lab nerve-cell line) against oxidative stress from copper-catalyzed amyloid-beta oxidation (damage caused when copper speeds up chemical reactions in amyloid-beta).
Tomasello MF, Di Rosa MC, Naletova I, Sciacca MFM, et al.
2013
Review of Semax and Selank by the group at the Institute of Molecular Genetics RAS that developed them (Neuroscience & Medicine 4:223-252). Replacing the last three amino acids (C-terminal residues) of ACTH(4-10) with Pro-Gly-Pro gave the longest-acting copy: its effect lasts 20-24 h versus 30-60 min for ACTH(4-10). Semax forms fairly stable active breakdown products (intermediates). It has no corticotropic activity (it does not act like the stress hormone ACTH on the adrenal glands) and no melanocyte-stimulating activity (it does not darken the skin). About 0.093% crosses the blood-brain barrier 2 min after a dose into the nose, versus about 0.01% after an intravenous (into a vein) dose. This is the basis for recommending the nasal route. The review reports dopamine and serotonin effects in rodents, and brain protection in ischemia (when blood flow to the brain is cut off), including blocking oxidative-stress reactions (damage from unstable molecules). It also reports that Semax 1% was well tolerated in stroke patients (discoloration of the lining of the nose in 10%, a mild rise in blood sugar in 7.4% of patients with diabetes). It describes Selank as a pronounced anxiolytic (anti-anxiety agent) that boosts serotonin metabolism (how the body handles serotonin).
Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N